BUZZ-<a href="https://laohu8.com/S/ILMN">Illumina</a> rises after co set for global launch of cancer test next year** Gene-sequencing equipment maker Illumina's ILMN.O shares rise 1.3% to $132.44
** ILMN's TruSight Oncology 500 v2, a cancer test that uses genetic profiling of blood for DNA fragments of tumor, is set to launch globally in mid-2025, co says
** The test kits are now available to ship in the U.S. after FDA approved it and its companion diagnostics in August - ILMN
** Fourteen of 26 brokerages rate the stock "buy" or higher, 11 "hold" and 1 "sell"; their median PT is $162 - LSEG
** Including session's gains, stock had fallen 2.5% YTD vs 3.5% YTD increase in Dow Jones US Health Care index .DJUSHC
(Reporting by Kamal Choudhury)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments